The Law Offices of Frank R. Cruz Announces Investigation of Amryt Pharma plc (AMYT) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Amryt Pharma plc (“Amryt ” or the “Company”) (NASDAQ: AMYT) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On February 28, 2022, Amryt disclosed receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) stating that the Company’s New Drug Application for its Dystrophic and Junctional Epidermolysis Bullosa (“EB”) treatment, Oleogel-S10, could not be approved in its current form. The FDA “asked Amryt to submit additional confirmatory evidence of effectiveness for Oleogel-S10 in EB.”

On this news, Amryt’s American Depositary Share (“ADS”) price fell $1.15, or 14.2%, to close at $6.98 per ADS on February 28, 2022, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Amryt securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [e-mail], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.